Smart scans may slash radiation doses for metastatic prostate cancer

NCT ID NCT07674771

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This early-phase trial explores whether PSMA PET scans can help doctors adjust radiation therapy for men with prostate cancer that has spread to 4 to 20 spots in the body. Participants receive standard hormone therapy plus a special PET scan, then targeted radiation to all visible tumors. A repeat scan after three radiation sessions may allow some tumors to skip the final two sessions if they show a complete response. The goal is to see if this adaptive approach can safely reduce the total radiation dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

68Ga-PSMA-11 and adaptive stereotactic ablative radiotherapy (SABR)

What this could lead to

If successful, this approach could reduce the amount of radiation needed for each tumor site, potentially lowering side effects while maintaining cancer control.

What could go wrong

This is a very early-phase trial with only 30 participants, so results may not apply broadly. The imaging and radiation technique may not shrink tumors as expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••